NL-OMON26066招募中不适用
Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility study
eiden University Medical Center0 个研究点目标入组 12 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Aged between 1-18 years at the time of hematopietic stem cell tranplantation (HSCT)
- •- Undergoing HSCT for acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML) according to existing indications
- •- Receiving a stem cell graft from a mismatched family or volunteer unrelated donor
- •- Life expectancy>3 months
- •- Availability of a stem cell donor willing to donate white blood cells by means of a non-mobilized leukapheresis procedure
排除标准
- •- Progressive uncontrollable malignant disease after HSCT but before or at the day of NK cell infusion, defined as overt leukemia relapse, i.e., ¡Ý 25% blasts in the marrow and/or 5% circulating blasts in the peripheral blood or progressive extra-medullary disease
- •- Lack of evidence for donor myeloid engraftment at the day of infusion (< 0.5 x 10e6 neutrophils/L);
- •- Active acute GvHD ¡Ý grade II (overall grade)
- •- Administration of steroids >1 mg/kg/day for any indication at the day of infusion
- •- Any medical condition, which in the opinion of the treating physician, would interfere with the adequate evaluation of the patient (e.g. end-stage irreversible multi-system organ failure)
- •- Cord blood stem cell donor
研究者
相似试验
已完成
不适用
Infusion of IL-15 activated NK cells after allogeneic stem cell transplantation in children transplanted for relapsed/refractory leukemia: a feasibility studyblood cell cancer10024324LeukemiaNL-OMON43758eids Universitair Medisch Centrum12
进行中（未招募）
不适用
Infusion of activated donor-derived NK cells after stem cell transplantation in children transplanted with high-risk leukemiaChildren with high-risk and recurrent acute leukemia are eligible for allogeneic hematopoietic stem cell transplantation (HSCT). However, leukemia relapse and viral infections after HSCT remain main reasons for treatment failure.MedDRA version: 14.1Level: LLTClassification code 10023685Term: LAK cell therapySystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2011-001514-34-NLeiden University Medical Center
进行中（未招募）
1 期
"Phase I / II Study on Infusion of Natural Killer Cells After Haploidentical Transplantation in Pediatric Patients"High-risk LeukemiasNCT05304754Instituto de Investigación Hospital Universitario La Paz18
招募中
1 期
Donor NK cell infusion for patients after allogeneic hematopoietic stem cell transplantatioacute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, chronic myelogenous leukemiaJPRN-UMIN000005138Hematology, Hyogo College of Medicine9
已完成
不适用
Infusion of ex vivo-cultured allogeneic NK cells in acute myeloid leukemia patients not eligible for stem cell transplantation (a phase I dose escalation study)Blood cancer10024324Acute Myeloid LeukemiaNL-OMON38045niversitair Medisch Centrum Sint Radboud15